RNS Number : 2847R
ValiRx PLC
05 July 2022

ValiRx Plc

("**ValiRx**" or the "**Company**")

Broker Option Results

Further to the announcement made on 30 June 2022 by the Company in connection with the placing to raise £1.5 million (before expenses) (the "**Fundraising Announcement**"), ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to announce that the Broker Option granted to Turner Pope Investments (TPI) Limited has been fully subscribed, receiving applications for 10,000,000 Ordinary Shares (representing £1.0 million raised before expenses) available on the same terms as the Fundraising.

Subject to Admission, trading in the new Ordinary Shares is expected to commence on Thursday, 7 July 2022.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 30 June 2022.

The Directors of the Company take responsibility for this announcement.

*** **ENDS** ***

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO	**Tel: +44 (0) 2476 796496** **www.valirx.com** Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 088**
Cenkos Securities Limited (Joint Broker) Dale Bellis/Michael Johnson (Sales) Giles Balleny/Callum Davidson (Corporate Finance)	**Tel: +44 (0) 20 7397 8900**
Turner Pope Investments (TPI) Limited (Joint Broker) James Pope / Andy Thacker	**Tel: +44 (0) 20 3657 0050**

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUSSRRUBUBRUR